Taysha completes dosing in REVEAL pivotal trial for Rett syndrome
Taysha Gene Therapies completed dosing in the REVEAL pivotal trial for Rett syndrome and reported positive data from Phase 1/2 trials, marking progress in its AAV-based gene therapy TSHA-102.
*this image is generated using AI for illustrative purposes only.
Taysha Gene Therapies, Inc. has completed dosing in the REVEAL pivotal trial evaluating TSHA-102 for the treatment of Rett syndrome. The company also reported positive longer-term clinical data from Part A of the REVEAL Phase 1/2 trials. TSHA-102 is an adeno-associated virus (AAV)-based gene therapy designed for severe monogenic diseases of the central nervous system (CNS).
Trial Details
The REVEAL pivotal trial focuses on the developmental plateau population of Rett syndrome. The completion of dosing marks a significant milestone in the clinical development of TSHA-102. The positive data from Part A of the Phase 1/2 trials supports the continued advancement of the therapy.
About TSHA-102
TSHA-102 is being developed as a potential treatment for Rett syndrome, a severe genetic neurological disorder. The therapy utilizes AAV-based gene therapy to target the underlying cause of the disease. The reported longer-term clinical data from the Phase 1/2 trials indicates promising results for patients.
What are the anticipated timelines for releasing top-line data from the REVEAL pivotal trial?
How might the positive Phase 1/2 data influence regulatory discussions and potential approval pathways?
What strategies could Taysha employ to scale manufacturing if TSHA-102 receives market approval?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
